Subscribe free

Cytoreductive Surgery & Peritoneum ·

Cytoreductive surgery improves survival in metastatic colorectal cancer.

National trends indicate that the utilization of cytoreductive surgery (CRS) for metastatic colorectal cancer (mCRC) increased from 33.1% in 2004 to 38.3% in 2015. In a cohort of 88,593 patients, those undergoing CRS exhibited significantly better overall survival (OS) compared to non-surgical patients, with median OS at 34.4 months, versus 13.2 months for no surgery. Additionally, patients receiving hyperthermic intraperitoneal chemotherapy (HIPEC) showed further OS improvement (30.2 months) compared to non-HIPEC patients.

Journal Article by Young S, Greene J (…) Bilchik A et 3 al. in J Surg Oncol

© 2025 Wiley Periodicals LLC.

read the whole article in J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →